Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) - Business Wire

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)  Business WireFDA approves Rocket gene therapy for rare immune disorder  statnews.comRocket Pharma shares fall despite FDA nod for childhood disorder treatment  ReutersRocket plots measured trajectory for new gene therapy Kresladi after clearance to launch from FDA  Fierce PharmaFDA approves gene therapy for severe leukocyte adhesion deficiency-I, a rare immune disorder  UCLA Health